Longaeva Partners’s Immunome IMNM Stock Holding History

Longaeva Partners’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-102,500	Closed	-$2.2M	–	228
2025 Q4	$2.2M	Buy	+102,500	New	+$1.8M	0.18%	90

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Longaeva Partners's IMNM Position: Q1 2026 in Review

Longaeva Partners sold out of Immunome (IMNM) in Q1 2026, closing a stake of 102,500 shares — an estimated $2.2M sold.

Longaeva Partners first reported a position in IMNM in Q4 2025 and held it in 1 quarter. The position peaked at $2.2M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

Longaeva Partners reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
Longaeva Partners sold 102,500 Immunome shares in Q1 2026, an estimated $2.2M.
Longaeva Partners first reported a position in Immunome in Q4 2025 and held it in 1 quarter.
Longaeva Partners's Immunome position peaked at $2.2M in Q4 2025.
200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Longaeva Partners's 13F filing for Q1 2026, filed 15 May 2026.